PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11499897

Amphetamines: an update on forensic issues.

B K Logan
View original source ↗Export metadata ↓

Abstract

Methamphetamine is currently enjoying a resurgence of popularity as a recreational drug. It presents a number of challenges to the forensic toxicologist both analytically and interpretively, and these latter interpretive issues are considered here. This review also discusses the current popular syntheses which account for the widespread domestic synthesis of the drug; the demographics of methamphetamine use in the United States as assessed from the Drug Abuse Warning Network (DAWN) data; developments in research of the neurotransporter pharmacology of the drug and its implications for interpretive forensic toxicology; the psychomotor effects of the drug and its potential for cognitive and functional impairment; interpretive issues related to postmortem blood drug concentrations and how these are impacted by evidence for incomplete distribution and the potential for postmortem redistribution; and, finally, concerns caused by designer methamphetamine analogues. All data indicate that methamphetamine and its analogues will present significant interpretive challenges to forensic toxicologists as the popularity of the drug continues to grow.

Explore related subjects

Amphetamine-Related DisordersDemographyForensic MedicineMethamphetamineSubstance Abuse DetectionUnited StatesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B K Logan. Amphetamines: an update on forensic issues.. https://doi.org/10.1093/jat%2F25.5.400

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Lifetime correlates associated with amphetamine use among northern Thai men attending STD and HIV anonymous test sites.

AIMS: To investigate the demographic, sexual, and other substance use risk correlates of amphetamine use among men in northern Thailand prior to the current epidemic of amphetamine use in the Kingdom. DESIGN: Cross-sectional quantitative behavioral questionnaires. SETTING: Thai Ministry of Health STD and HIV Anonymous Test Sites in the upper northern provinces of Chiang Mai and Lamphun. PARTICIPANTS: Adult Thai men recruited at clinics for enrollment in an HIV seroincidence cohort study (The Thai HIVNET). All men were HIV negative at enrollment, and had at least one self-reported sexual risk for HIV infection (a recent STD, use of sex workers, multiple sexual partners, low or absent condom use, sex with men). MEASUREMENTS: Participants answered a structured questionnaire. FINDINGS: Lifetime history of amphetamine use was reported by 133/914 men, 14.5%. Older age was protective for use (odds ratio (OR) 0.5) and use was associated with use of other substances; heroin (OR 7.1), thinner (OR 6.2), opium (OR 5.9), and marijuana (OR 5.7). Several STDs were associated with amphetamine use: gonorrhea (OR 2.3) and genital warts (OR 2.4), and any STD (OR 1.9). In multivariate analysis, use of heroin (OR 3.1), soft drugs (OR 4.9), and a history of gonorrhea (OR 2.0) were independently associated with amphetamine use in northern Thai men. CONCLUSIONS: Associations between young age, gonorrhea, other substance use and amphetamines indicate that prevention measures could occur at STD clinics and be incorporated into school programs when individuals are entering adolescence.

Amphetamine-Related Disorders↗
PubMed2002

Baclofen decreases methamphetamine self-administration in rats.

In the present study we tested the hypothesis that baclofen, a GABA-B receptor agonist, attenuates methamphetamine self-administration. Fifteen rats were trained to self-administer i.v. injections of methamphetamine (0, 0.0625, 0.125 and 0.25 mg/kg/injection) on a progressive ratio schedule of reinforcement, and then were tested under the influence of two doses of baclofen (2.5 or 5.0 mg/kg, i.p.). Baclofen significantly reduced break points at all doses of methamphetamine, producing a dose-orderly shift of the methamphetamine dose-response function to the right. These data suggest that pretreatment with baclofen reduces methamphetamine reward. These data are consistent with other studies showing impairment of drug reward after pretreatment with baclofen and add further support to the idea that GABA-B agonists may be useful in the treatment of drug addiction.

Amphetamine-Related Disorders↗